Xlumena closed a $4.8 million debt and securities round with 10 unnamed investors.
Founded in 2007, the Mountain View, Calif.-based company makes ultrasound-guided interventional microscopes, including an FDA-cleared pancreatic cyst access device called Navix.
Xlumena is wrapping up clinical trials to support a 510(k) application for its Axios stent and delivery system, also to treat pancreatic cysts.
The recent funding round was an amended round that originally kicked off in April, according to an SEC filing. The company roped in $7 million in a Series B funding round in 2011. Backers then included Aperture Venture Partners, Western Technology Investment, Prism Ventures, Charter Life Sciences and Ascent Biomedical Ventures.